Dr Michael Pishvaian from the Johns Hopkins University School of Medicine in Washington, DC, discusses recent therapeutic advances in pancreatic cancer.CME information and select publications here (http://www.researchtopractice.com/OncologyTod
Go online to PeerView.com/BDQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The availability of poly (ADP-ribose) polymerase (PARP) inhibitors has increased opportunities for healthcare p
Featuring an interview with Dr Michael Pishvaian, including the following topics: Case: A woman in her late 50s with metastatic pancreatic cancer with diffuse liver metastases (0:00) Case: A woman in her mid-60s with resectable pancreatic canc
Dr Jain discusses the current utility of frontline maintenance therapy in advanced ovarian cancer, dosing strategies with PARP inhibitors, and management strategies for common adverse effects associated with these therapies.
Go online to PeerView.com/YWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you optimizing the care of your patients with ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhib